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Aims Iron deficiency (ID) is a common co-morbidity in heart failure (HF), associated with impaired functional capacity,
poor quality of life and increased morbidity and mortality. Treatment with intravenous (i.v.) ferric carboxymaltose
(FCM) has shown improvements in functional capacity, symptoms and quality of life in stable HF patients with reduced
ejection fraction. The effect of i.v. iron supplementation on morbidity and mortality in patients hospitalised for acute
HF (AHF) and who have ID has yet to be established. The objective of the present article is to present the rationale
and design of the AFFIRM-AHF trial (ClinicalTrials.gov NCT02937454) which will investigate the effect of i.v. FCM (vs.
placebo) on recurrent HF hospitalisations and cardiovascular (CV) mortality in iron-deficient patients hospitalised
for AHF.
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Methods AFFIRM-AHF is a multicentre, randomised (1:1), double-blind, placebo-controlled trial which recruited 1100 patients
hospitalised for AHF and who had iron deficiency ID defined as serum ferritin <100 ng/mL or 100–299 ng/mL if
transferrin saturation <20%. Eligible patients were randomised (1:1) to either i.v. FCM or placebo and received
the first dose of study treatment just prior to discharge for the index hospitalisation. Patients will be followed
for 52 weeks. The primary outcome is the composite of recurrent HF hospitalisations and CV mortality. The
main secondary outcomes include the composite of recurrent CV hospitalisations and CV mortality, recurrent HF
hospitalisations and safety-related outcomes.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion The AFFIRM-AHF trial will evaluate, compared to placebo, the effect of i.v. FCM on morbidity and mortality in
iron-deficient patients hospitalised for AHF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Acute heart failure • Iron deficiency • Ferric carboxymaltose • Recurrent heart failure
hospitalizations • Cardiovascular mortality
Introduction
Hospitalisation for acute heart failure (AHF) is frequent and is asso-
ciated with post-discharge heart failure (HF) readmission rates of
between 30% and 40% in the following 6 months.1–3 Additionally,
mortality in these patients remains unacceptably high – the recent
European Society of Cardiology (ESC) Heart Failure Long-Term
Registry reports 1-year mortality in AHF patients reaching almost
24%.4–6 Currently, there is no evidence-based therapy which
has improved clinical outcomes, mortality and morbidity in this
population.7
Acute HF represents a broad spectrum of disease states, with
heterogeneous clinical presentations, but may be characterized by
either a progressive or rapid onset of worsening of signs and symp-
toms, leading to urgent hospitalisation. Co-existing cardiovascular
(CV) and non-CV co-morbidities are common in patients hospi-
talised for AHF and these co-morbidities impact on the manage-
ment and the natural course in this acute phase of the disease.
The 2016 ESC HF guidelines endorse that co-morbidities should
be considered when defining the overall treatment management
strategies for HF patients, with HF syndrome.8
Iron deficiency (ID) is recognized as a prevalent co-morbidity in
HF, and is known to be present in approximately 50% of patients
with stable HF irrespective of the presence of anaemia. In addition,
ID has been shown to be an independent predictor of morbidity
and mortality in such patients.9–12
Iron is necessary for a multitude of processes within the human
body, such as oxygen transport and storage, cardiac and skeletal
muscle metabolism, energy production in the mitochondria (via the
Krebs cycle and respiratory chain reaction), synthesis and degra-
dation of proteins, lipids and ribonucleic acid.13–15 In order to
meet the high energy demands of the heart, cardiomyocytes con-
tain many mitochondria, with iron being an essential component
of energy production.10,16–20 The effect of ID on the function of
the heart itself, such as a decrease in energy production in the
mitochondria and adverse effects on cardiomyocyte contractility
and relaxation, has been evidenced by recent pre-clinical studies.
An in vitro model showed that by restoring intracellular iron lev-
els these adverse effects could be reverted.21 In particular during



























































. glycolysis and extracellular lactate production, whilst decreasing
mitochondrial aerobic pathway in cardiomyocytes.22 Further, it
was demonstrated in an ID mouse model that impaired mito-
chondrial metabolism due to ID results in reduced physical per-
formance and decreased left ventricular function. After treatment
with intravenous ferric carboxymaltose (FCM), these abnormalities
reversed.23 The beneficial effects of FCM were confirmed in an ID
mouse model24 and an ID rat model,25 respectively.
Iron is essential for the transport and storage of oxygen, for
the oxidative metabolism in the skeletal and heart muscle and for
the synthesis and breakdown of lipids, carbohydrates, DNA and
RNA.14,26 ID leads to mitochondrial dysfunction, and the negative
impact of ID is seen predominantly in tissues with a high-energy
demand, such as skeletal and heart muscles.18,21,22,27–30 Iron is thus
indispensable for the correct functioning of both haematopoietic
and non-haematopoietic tissues.14,31
Pathophysiological consequences of ID in HF are multifacto-
rial but are still not well characterized (Figure 1). In the presence
of impaired erythropoiesis and concomitant anaemia, deleterious
effects are associated with low haemoglobin and resemble that
seen in anaemic HF patients.32 On the other hand, the presence of
ID alone results in decreasing oxygen storage in myoglobin, abnor-
mal oxidative metabolism and cellular energy handling, impaired
reactive oxygen species defense,18,33 all of which contribute to an
exacerbation of mitochondrial dysfunction – one of the key under-
lying pathologies of the HF syndrome.17 Recent studies report that
ID in HF contributes to abnormal muscle function with specific
form of skeletal myopathy.27,34–36
It has been suggested that ID could be present in up to
80% of patients hospitalised for AHF.37,38 ID was found to be
a predictor of poor outcome, regardless of previous history of
HF, natriuretic peptide levels and ejection fraction (%), suggest-
ing that depleted iron stores may have a strong unfavourable
impact on the natural history of this clinical syndrome beyond
the CV status.39,40 The mechanisms underlying the unfavourable
outcomes related to a depleted iron status in AHF have yet
to be investigated in a clinical setting. An episode of worsen-
ing HF is a clinical entity, where the maintenance of energetic
homoeostasis is of fundamental importance, not only at the level
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Role of iron in cell metabolism.
of the failing myocardium, but also in the other organs criti-
cal to struggle with decompensation (kidneys, liver, and skeletal
muscles). There may be an association between bioenergetic
inefficiency due to decreased iron content and abnormal handling
of the latter. In addition, together with the combination of worsen-
ing neuroendocrine and pro-inflammatory activation, and oxidative
stress, all factors would unfavourably impact on the duration of
hospitalisation and on the early post-discharge phase where the
risk of readmission and death is the highest. Therefore, correcting
ID in patients recently hospitalised for AHF may be an attractive
and easily implemented treatment option for such patients.
Randomized clinical trials (RCTs) have shown that treatment
with intravenous (i.v.) FCM improves functional capacity, exercise
tolerance, symptoms and quality of life in stable HF with reduced
ejection fraction (HFrEF) patients with ID.41–43 A recent individual
patient data meta-analysis also suggested that treatment of ID with
i.v. FCM in ambulatory systolic HF patients may decrease recurrent
CV hospitalisations and thus i.v. FCM may potentially represent a
beneficial addition to the standard medical management of HF.44
However, the impact of treatment with i.v. FCM on morbidity and
mortality in HF patients admitted for an episode of AHF and who
present in addition with ID is unknown. The AFFIRM-AHF trial
is the first adequately powered trial to investigate this, relative
to placebo, the effect of i.v. FCM on mortality and morbidity in
iron-deficient patients hospitalised for AHF.
Study design
The AFFIRM-AHF trial is a multicentre, randomised (1:1), placebo-
controlled, double-blind superiority study, which was designed by
members of the steering committee in collaboration with the
sponsor (NCT02937454).
Between April 2017 and 31 July 2019, 1100 patients were



















































.. in Western and Eastern Europe, Middle East, South America,
and Asia (Singapore). Each patient will be followed for 52
weeks.
The trial, which is conducted in strict compliance with Good
Clinical Practice from the International Council for Harmonisation
(ICH GCP) and with the Declaration of Helsinki, was approved by
the appropriate Regulatory Authorities and Ethics Committees. All
patients who agreed to participate were asked to provide written
informed consent before any trial-related procedure is performed.
Patient population
Male or female patients aged ≥18 years and who are hospitalised
(i.e. index hospitalisation) with the primary reason of AHF, were
considered for participation. Eligible patients must have presented
with typical signs, symptoms of AHF, must have elevated natriuretic
peptides and must be treated with minimally furosemide 40 mg
i.v. (or equivalent i.v. diuretic) (Table 1). Left ventricular ejection
fraction, not older than 12 months at the time of randomisation,
must be <50%. Patients must have ID, defined as serum ferritin
<100 ng/mL or 100 ng/mL≤ serum ferritin ≤299 ng/mL if transfer-
rin saturation<20%. The key inclusion/exclusion criteria are shown
in Table 1 and the complete inclusion and exclusion criteria are
shown in online supplementary Table S1.
Study procedures and visit schedule
The study procedures and visit schedule are shown in Figure 2. The
first dose of study treatment was administered before discharge
for the index hospitalisation. Following discharge, patients were
contacted either by telephone or in-person at the outpatient clinic
at the defined time-points shown in Figure 2.
At each contact, the patient’s well-being in addition to the
occurrence of adverse events and/or hospitalisations is evaluated.
Patients are requested to complete the self-administered Kansas
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Main inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Relating to the index hospitalisation
• Primary reason for index hospitalisation: acute HF
• Presented with typical signs, symptoms of acute HF
• BNP ≥400 pg/mL or NT-proBNP ≥1600 pg/mL; AF present,
BNP ≥600 pg/mL or NT-proBNP ≥2400 pg/mL obtained
maximally 72 h after admission
• Treated with minimally 40 mg i.v. furosemide or equivalent
Cardiovascular-related
• Dyspnoea of non-CV origin
• Clinical evidence of ACS, TIA or stroke within the last 30 days
• CABG, PTCA, cardiac device implant/resynchronisation therapy or
major surgery leading to significant blood loss within last 30 days
Other medical conditions
• Hb <8 g/dL (<10 g/dL for sites in The Netherlands, Spain and
Singapore) or Hb >15 g/dL
• Known anaemia not attributed to ID or history of iron overload
• Known severe allergies
• ESA, i.v. iron or blood transfusion administered in last 3 months
• Oral iron (>100 mg/day) in previous 4 weeks
Iron status
• Iron deficient: serum ferritin <100 ng/mL or if TSAT <20%,
100 ng/mL ≤ serum ferritin ≤299 ng/mL
Ejection fraction measurement
• Left ventricular ejection fraction not older than 12 months,
<50%
ACS, acute coronary syndrome; AF, atrial fibrillation; BNP, brain natriuretic peptide; CABG, coronary artery bypass grafting; CV, cardiovascular; ESA, erythropoietin-stimulating
agent; Hb, haemoglobin; HF, heart failure; ID, iron deficiency; i.v., intravenous; NT-proBNP, N-terminal pro-brain natriuretic peptide; PTCA, percutaneous transluminal coronary
angiography; TIA, transient ischaemic attack; TSAT, transferrin saturation.
City Cardiomyopathy Questionnaire. During the outpatient clinic
visits, blood samples are drawn and analysed locally to determine
serum ferritin, transferrin saturation, haemoglobin, and phos-
phorus. A biomarker blood sample is be drawn in a subset of
consenting patients. During the outpatient visits, vital signs will
be measured and HF signs/symptoms evaluated, including New
York Heart Association functional class. Throughout the follow-up
period, patients continue to receive their standard therapy for HF
and medical emergencies treated according to local routine.
Randomisation and study treatment
dosing regimen
Patients were randomised to either FCM or placebo using a secure
web-based randomisation system and subject randomisation was
determined by a minimisation algorithm. The study treatment
dosing phases was based on a repletion and a maintenance phase.
The first and second study treatment doses were determined
using the patient’s screening visit body weight measurement and
haemoglobin value (Table 2). During the outpatient clinic visits
at weeks 12 and 24, study treatment was administered if ID
persisted, based on the laboratory test results performed at the
respective visits.
Study treatment is prepared by unblinded site personnel using
black syringes and, once prepared, is administered thereafter using
a curtain (or similar) to maintain patient blinding. Each patient
remains under observation for at least 30 minutes after each
study treatment administration. The unblinded site personnel are
not operationally involved in performing any study assessments
(efficacy or safety) for the patient concerned.
Study outcomes
The primary outcome is the composite of recurrent HF hospitalisa-



















































.. i.v. FCM with placebo (Table 3). The secondary outcomes are
shown in online supplementary Table S2.
Sample size considerations
and statistical analysis
Sample size calculations were done using data from the EVEREST
trial and ESC HF registry.45,46 Compared to the placebo group,
it was assumed that there would be a 30% reduction in HF hos-
pitalisations for patients allocated to FCM and that CV mortality
rates would be similar between the FCM and placebo groups.
The rate ratio between FCM and placebo for the composite of
recurrent HF hospitalisations and CV mortality was estimated to
be approximately 25%.
Based on these assumptions, it was determined that in total
1000 patients (500 per treatment group) would be required to
demonstrate a statistically significant rate ratio of 0.75 (i.e. 25%
reduction of recurrent events between the FCM and placebo
groups) with a power of 80% and a two-sided alpha of 0.05.
Assuming a 9% loss to follow-up, a sample size of 1100 patients
(550 per treatment group) was planned. The sample size calcula-
tion was done using NCSS PASS-14,47 using the sample size formula
proposed by Zhu and Lakkis48 comparing two negative binomial
rates.
All analyses will be detailed in a Statistical Analysis Plan which
will be finalised prior to database lock and unblinding. Tabulations
will be produced for appropriate demographic, baseline, efficacy,
and safety parameters. For categorical variables, summary tab-
ulations of the number and percentage of subjects within each
category for the parameter concerned will be presented (with a
category for missing data if appropriate). For continuous variables,
the mean, median, standard deviation, first and third quartiles,
and minimum and maximum values will be presented. The level
of significance to be used for tests will be 0.05. The analyses
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Rationale and design of AFFIRM-AHF 1655
Figure 2 Study procedures and visit schedule. AHF, acute heart failure; ID, iron deficiency; FCM, ferric carboxymaltose; PL, placebo; V, visit;
W, week.
Table 2 Study treatment dosing regimen
Hb, haemoglobin; ID, iron deficiency.
(1)10 g/dL for patients from The NL, Spain and Singapore.
(2)Dosing at Week 6 (Visit 3) – second repletion dose; Study treatment will only be administered in subjects for whom Hb ≤15 g/dL.
(3)10ml of study treatment contained either 500 mg iron or 10 ml of normal saline. ID defined as serum ferritin <100 ng/mL, or 100 ng/mL ≤ serum ferritin ≤299 ng/mL if
transferrin saturation (TSAT) <20%.
will be performed on the full-analysis set in accordance with the
intention-to-treat principle. The adjudicated data will be used
in the analysis for hospitalisations and cause of death. For the
recurrent event analysis, descriptive statistics (total number of
events, number of subjects with at least one event, number of
events per subject, follow-up duration, rate per 100 subject-years)
will be provided, and a negative binomial model will be used
to estimate the rate ratio between treatment groups. A sen-
















Four committees – Steering Committee, Executive Committee,
Data Safety Monitoring Committee (DSMC) and Adjudication
Committee (AC) – have been established for the AFFIRM-AHF
trial. The membership of these committees is shown in online
supplementary Table S3.
The Steering Committee oversees the scientific integrity of the
trial while the Executive Committee, a subset of the Steering
Committee, is responsible to oversee the operational conduct
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Primary and secondary outcomes
Primary outcome
• Composite of recurrent HF hospitalisations and CV death up to 52 weeks after randomisation
Secondary outcomes
• The composite of recurrent CV hospitalisations and CV death up to 52 weeks after randomisation
• HF hospitalisations up to 52 weeks after randomisation (analysed as recurrent event)
• CV mortality analysed as time to first event at 52 weeks after randomisation
• The composite of HF hospitalisations or CV death analysed as time to first event at 52 weeks after randomisation
• Days lost due to HF hospitalisations or CV death at 52 weeks after randomisation
CV, cardiovascular; HF, heart failure.
of the trial. The DSMC is composed of a group of independent
experts responsible to oversee patient safety. The DSMC will meet
and review patient data at the pre-specified time points defined in
the DSMC charter.
The AC independently adjudicate all hospitalisations and deaths
using the detailed criteria in the adjudication charter. The criteria
will follow that detailed by Hicks et al.49
Quality assurance and quality control
The investigator will be responsible to ensure that all trial-related
site source data, study-related documents and reports will be
available, and the provision of direct access for monitoring, auditing
and/or inspections.
Accurate and reliable data collection will be assured by source
data verification and cross-checking of the electronic case record
forms vs. the source data. A comprehensive validation check
programme will verify the data and queries will be generated
for resolution by the investigator. Audits will be performed in
accordance with the AFFIRM-AHF Quality Management Plan.
Discussion
The advances in the understanding of the pathophysiology of HF in
addition to the recent introduction of novel HF therapies has signif-
icantly reduced mortality in this clinical syndrome.50 As HF patients
are now living longer, they are exposed to numerous conditions
that may lead to clinical deterioration with subsequent need for
urgent hospital admissions with a diagnosis of AHF. Given that AHF
represents a broad spectrum of disease states, with heterogeneous
clinical presentation, the identification of existing co-morbidities
and in particular ID may well help clinicians to determine and direct
treatment strategies more correctly by targeting specific underlying
conditions and precipitating factors.5
Iron deficiency (ID) is one of the co-morbidities that are
commonly present in HF and AHF and is a predictor of poor
outcomes, thus suggesting that depleted iron stores may have
an unfavourable impact on the natural course of this clinical
syndrome.39,40 Interestingly, the pattern of deranged iron status
seen in AHF, characterized by depleted iron stores accompanied
by unmet cellular iron requirements for maintenance of energetic
































































. risk of death after an episode of AHF.39 Preservation of optimal
energetics in the myocardium and the end-organs may be of key
importance to effectively overcome all deleterious consequences
of cardiac decompensation.
Currently, there is no evidence-based therapy that has improved
clinical outcomes, mortality and morbidity in AHF.1–3,7 This thus
points in the direction that the identification and targeting of
co-morbidities is an important component of the treatment
strategy in AHF. Current HF guidelines for the treatment of HF
recommend identification of co-morbidities and to take them into
consideration when planning an overall treatment strategy for the
HF patient in both the ambulatory and acute settings.8
Recent studies have demonstrated that in stable HFrEF patients
with ID, the supplementation with i.v. iron in iron-deficient HFrEF
patients has a positive impact on physical performance and quality
of life.41–43,51 There are, however, no RCTs that have investigated
if the supplementation with i.v. FCM in iron-deficient patients
recently admitted for an AHF episode has a favourable impact on
mortality and morbidity.
In designing the AFFIRM-AHF trial, the presence (or not) of ID
during the index hospitalisation will be evaluated with a blood test
taken after stabilisation during the index hospitalisation for AHF,
and thus, does not create any additional burden for the treating
physician. According to the current HF guidelines,8 identification
of co-morbidities should be part of the treatment strategy for HF
patients, so this will also help to increase the awareness of the need
to check iron status in patients hospitalised for AHF. Regarding
the latter, the post-discharge period is considered as the most
‘vulnerable’ phase in the natural history of a HF patient, with a high
risk of hospital readmission or death.52 The supplementation of i.v.
iron in iron-deficient patients during this post-discharge period may
be efficacious to improve the outcome in this phase.
The impact of the supplementation of i.v. FCM on morbidity
and mortality in iron-deficient patients hospitalised for AHF has
yet to be established. The AFFIRM-AHF is the first adequately
powered RCT that addresses the question whether i.v. FCM,
compared to placebo, in stabilised iron-deficient patients following
AHF is superior regarding the favourable effect on mortality and
morbidity. In designing this trial we aimed to be pragmatic and
mirror clinical practice, as an administration of i.v. FCM is easily
done in clinical practice and there are no restrictions with respect
to treatments for HF either during the in-hospital or post-discharge
phases. In addition, this trial will enable the collection of safety
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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data concerning the use of i.v. FCM when administered in patients
stabilised after an AHF episode.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. AFFIRM-AHF – complete inclusion and exclusion
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